- Home
- FLC vs NGEN Comparison
FLC vs NGEN Comparison
Compare FLC & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FLC | NGEN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.8M | 197.5M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | FLC | NGEN |
|---|---|---|
| Price | $16.61 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 17.9K | ★ 739.3K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.89 | $1.59 |
| 52 Week High | $18.09 | $5.93 |
Technical Indicators
Market Signals| Indicator | FLC | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 32.53 |
| Support Level | $16.59 | N/A |
| Resistance Level | $17.00 | $2.22 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 13.64 | 2.32 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.